- Home
- AEE vs UTHR Comparison
AEE vs UTHR Comparison
Compare AEE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEE
- UTHR
- Stock Information
- Founded
- AEE 1901
- UTHR 1996
- Country
- AEE United States
- UTHR United States
- Employees
- AEE N/A
- UTHR N/A
- Industry
- AEE Power Generation
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- AEE Utilities
- UTHR Health Care
- Exchange
- AEE Nasdaq
- UTHR Nasdaq
- Market Cap
- AEE 18.7B
- UTHR 15.5B
- IPO Year
- AEE N/A
- UTHR 1999
- Fundamental
- Price
- AEE $91.20
- UTHR $363.25
- Analyst Decision
- AEE Buy
- UTHR Buy
- Analyst Count
- AEE 13
- UTHR 14
- Target Price
- AEE $85.36
- UTHR $370.86
- AVG Volume (30 Days)
- AEE 1.6M
- UTHR 390.1K
- Earning Date
- AEE 11-06-2024
- UTHR 10-30-2024
- Dividend Yield
- AEE 2.94%
- UTHR N/A
- EPS Growth
- AEE N/A
- UTHR 25.10
- EPS
- AEE 4.26
- UTHR 22.72
- Revenue
- AEE $7,058,000,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- AEE $5.22
- UTHR $26.32
- Revenue Next Year
- AEE $5.70
- UTHR $10.37
- P/E Ratio
- AEE $21.43
- UTHR $15.99
- Revenue Growth
- AEE N/A
- UTHR 25.04
- 52 Week Low
- AEE $67.03
- UTHR $208.62
- 52 Week High
- AEE $92.77
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- AEE 60.19
- UTHR 42.87
- Support Level
- AEE $85.70
- UTHR $396.52
- Resistance Level
- AEE $92.77
- UTHR $417.82
- Average True Range (ATR)
- AEE 1.89
- UTHR 12.41
- MACD
- AEE 0.30
- UTHR -0.95
- Stochastic Oscillator
- AEE 79.07
- UTHR 26.51
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves more than 2.4 million electricity customers and more than 900,000 natural gas customers.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.